Stanley Druckenmiller's CDTX Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 49,495 shares of Cidara Therapeutics, Inc. (CDTX) worth $10.93 M, representing 0.24% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in CDTX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Cidara Therapeutics (CDTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cidara Therapeutics (CDTX) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +49,495 | New Buy | 49,495 | $220.89 |
Stanley Druckenmiller's Cidara Therapeutics Investment FAQs
Stanley Druckenmiller first purchased Cidara Therapeutics, Inc. (CDTX) in Q4 2025, acquiring 49,495 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Cidara Therapeutics, Inc. (CDTX) for 1 quarters since Q4 2025.
Stanley Druckenmiller's largest addition to Cidara Therapeutics, Inc. (CDTX) was in Q4 2025, adding 49,495 shares worth $10.93 M.
According to the latest 13F filing for Q4 2025, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 49,495 shares of Cidara Therapeutics, Inc. (CDTX), valued at approximately $10.93 M.
As of the Q4 2025 filing, Cidara Therapeutics, Inc. (CDTX) represents approximately 0.24% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Cidara Therapeutics, Inc. (CDTX) was 49,495 shares, as reported at the end of Q4 2025.